LILRB4 and acute myeloid leukemia: Su et al. found that inhibition of FTO by genetic depletion or pharmacological antagonist can sensitizes acute myeloid leukemia (AML) cells to T cell cytotoxicity by suppressing Leukocyte Immunoglobulin Like Receptor B4 (LILRB4) (81).